Background

Different countries have their own systems for evaluating new medicines, and they make decisions as to when and how each new medicine is adopted.

Purpose

To compare the rate of uptake of new diabetes medicines (dipeptidyl peptidase-4 inhibitors [DPP-4Is], glucagon-like peptide-1 receptor agonists [GLP1-RAs], and sodium-glucose co-transporter-2 inhibitors [SGLT2Is]) in the five most populated European countries.

Methods

The monthly volume of sales of antidiabetic drugs was extracted for each country from the IQVIA™ MIDAS® database for the period 2007 to 2016 and the defined daily doses (DDDs) were calculated. For each new drug, market shares were expressed as a percentage of the total market of non-insulin antidiabetic agents.

Results

Sharp differences were observed between the countries. Overall, the highest and fastest rates of uptake were seen for Germany and Spain, compared to lower rates for the UK and Italy. This was especially marked for DPP-4Is, where the market share reached over 30% of non-insulin antidiabetic drugs in Germany and Spain, compared to around 10% in the UK and Italy. In France, there was an initial rapid uptake, which stabilized at around 20% after three years. Rates of uptake were lower for the other drugs, with the GLP1-RAs reaching a market share of 2.5–4.5% in Germany, Spain and France, compared to less than 2.5% in the UK and Italy. The SGLT2Is reached a market share of 5–8% in Spain and Germany, compared to less than 4% in the UK and Italy, and they were not launched at all in France in March 2020.

Conclusion

The differences in the uptake of new antidiabetic drugs may reflect different methods for assessing and introducing new medicines, as well as cultural factors. The uptake of the new medicines would appear to be more cautious in the UK and Italy, perhaps due to concerns about cost-effectiveness, whereas in Germany and Spain, and possibly also France, a new medicine's potential benefits may be prioritized.

中文翻译：

---

欧洲新医药产品的渗透率：最近在 2 型糖尿病中启动的几个类别的比较研究

背景

不同的国家有自己的评估新药的系统，他们决定何时以及如何采用每种新药。

目的

比较新型糖尿病药物（二肽基肽酶 4 抑制剂 [DPP-4Is]、胰高血糖素样肽 1 受体激动剂 [GLP1-RAs] 和钠-葡萄糖协同转运蛋白 2 抑制剂 [SGLT2Is]）的服用率在欧洲人口最多的五个国家。

方法

从 IQVIA™ MIDAS® 数据库中提取了 2007 年至 2016 年期间每个国家/地区的每月抗糖尿病药物销售量，并计算了限定日剂量 (DDD)。对于每种新药，市场份额以占非胰岛素抗糖尿病药物总市场的百分比表示。

结果

观察到国家之间的显着差异。总体而言，德国和西班牙的吸收率最高和最快，而英国和意大利的吸收率较低。DPP-4I 的市场份额尤其显着，在德国和西班牙，非胰岛素抗糖尿病药物的市场份额达到 30% 以上，而在英国和意大利则为 10% 左右。在法国，最初的吸收速度很快，三年后稳定在 20% 左右。其他药物的吸收率较低，GLP1-RA 在德国、西班牙和法国的市场份额为 2.5-4.5%，而在英国和意大利则不到 2.5%。SGLT2I 在西班牙和德国的市场份额达到了 5-8%，而在英国和意大利则不到 4%，而且它们于 2020 年 3 月在法国根本没有推出。

结论

新抗糖尿病药物吸收的差异可能反映了评估和引入新药的不同方法，以及文化因素。可能是出于对成本效益的担忧，英国和意大利对新药的采用似乎更加谨慎，而在德国和西班牙，可能还有法国，新药的潜在益处可能会被优先考虑。